子宮頸がんワクチンの世界市場レポート 2024

子宮頸がんワクチンの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.3%の年間複合成長率（CAGR）で1,170億1,000万米ドルに成長すると予想されます。予測期間の伸びは、ワクチン接種範囲の拡大、定期予防接種プログラムへの統合、HPV検査とスクリーニングの進歩、HPVワクチン接種に対する世界の支持、および青少年のワクチン接種への注目の高まりに起因すると考えられます。予測期間の主な動向には、新しいアジュバントの導入、デジタルヘルスプラットフォームの統合、革新的なワクチン開発、官民パートナーシップ、教育キャンペーンと権利擁護が含まれます。

子宮頸がんワクチン市場の成長軌道は、子宮頸がんの罹患率の拡大によって急成長すると予想されます。子宮頸がんは子宮の下部に発生し、子宮頸がんの報告数が増加しています。その主な原因としては、不十分なヒトパピローマウイルス（HPV）ワクチン接種、劣悪な衛生習慣、子宮頸がんに関する認識と知識の不足などが挙げられます。特に、子宮頸がんワクチンは、高リスクタイプのヒトパピローマウイルス（HPV）を標的とすることで、この病気の予防において極めて重要な役割を果たします。たとえば、2023年 1月に米国がん協会は、米国だけで13,960件の子宮頸がんの症例を報告しました。その結果、子宮頸がんの発生率の増加が子宮頸がんワクチン市場の成長の原動力となっています。

ヘルスケア支出の急増は、子宮頸がんワクチン市場の拡大に大きく貢献しています。ヘルスケア支出は、特定の地域または国のヘルスケア部門に割り当てられる財源の総額を表し、子宮頸がんワクチン接種の取り組みを支援する上で重要な役割を果たします。 子宮頸がんワクチンへの投資は、子宮頸がんの発症予防を目的とし、治療費に伴う経済的負担の軽減を目的としています。さらに、この戦略的な資源配分は、広範な医療介入の必要性を抑制することで、公衆衛生全体の成果を向上させ、長期的な費用対効果を促進することを目指しています。たとえば、2023年 3月に米国医師会が報告したように、米国の医療支出は2021年に2.7%増加し、総額4兆3,000億米ドルとなり、一人当たり平均12,914ドルとなりました。したがって、ヘルスケア支出の増加は、子宮頸がんワクチン市場の成長を推進する原動力として浮上します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の子宮頸がんワクチン市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• サーバリックス
• ガーダシル
• ガーダシル9
• 世界の子宮頸がんワクチン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の子宮頸がんワクチン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• バイオテクノロジー企業
• 学術および研究機関
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の子宮頸がんワクチン市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の子宮頸がんワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 子宮頸がんワクチン市場の競合情勢
• 子宮頸がんワクチン市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • Merck &Co Inc.
  • Novartis AG
  • Sanofi Pasteur

第31章 その他の大手および革新的な企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Moderna Inc.
• BioNTech SE
• CSL Limited
• Daiichi Sankyo Company Limited
• Sinovac Biotech Ltd.
• Bharat Biotech International Limited
• Serum Institute of India（SII）
• Walvax Biotechnology Co Limited
• Bavarian Nordic A/S
• CureVac NV
• Profectus Biosciences Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

The cervical cancer vaccine is designed to prevent cervical cancer by targeting high-risk types of human papillomavirus (HPV), the primary cause of most cervical cancer cases. These vaccines stimulate the body's immune response, generating antibodies to recognize and neutralize the HPV virus.

The main cervical cancer vaccines include Cervarix, Gardasil, and Gardasil 9. Cervarix is specifically formulated to protect against certain HPV strains associated with cervical cancer. These vaccines are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, reaching diverse end-users such as hospitals, biotechnology companies, academic and research organizations, among others.

The cervical cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides cervical cancer vaccine market statistics, including the cervical cancer vaccine industry global market size, regional shares, competitors with a cervical cancer vaccine market share, detailed cervical cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the cervical cancer vaccine industry. This cervical cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $82.74 billion in 2023 to $88.39 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to awareness campaigns, educational initiatives, government-led vaccination programs, the rising incidence of cervical cancer, recommendations from healthcare providers, and global efforts to prioritize women's health.

The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $117.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the expansion of vaccination coverage, integration into routine immunization programs, advancements in HPV testing and screening, global advocacy for HPV vaccination, and a rising focus on adolescent vaccination. Major trends in the forecast period include the incorporation of new adjuvants, integration of digital health platforms, innovative vaccine development, public-private partnerships, and educational campaigns and advocacy.

The growth trajectory of the cervical cancer vaccine market is anticipated to surge, propelled by the escalating prevalence of cervical cancer cases. Cervical cancer, affecting the lower part of the uterus known as the cervix, is witnessing an increase in reported cases, primarily attributed to factors such as inadequate Human papillomavirus (HPV) vaccination, poor hygiene practices, and limited awareness and knowledge concerning cervical cancer. Notably, cervical cancer vaccines play a pivotal role in preventing this disease by targeting high-risk types of human papillomavirus (HPV). For example, in January 2023, the American Cancer Society reported 13,960 cases of cervical cancer in the United States alone. Consequently, the rising incidence of cervical cancer cases serves as a driving force behind the growth of the cervical cancer vaccine market.

The upsurge in healthcare spending is significantly contributing to the expansion of the cervical cancer vaccine market. Healthcare spending, representing the total financial resources allocated to the healthcare sector within a specific region or country, plays a crucial role in supporting cervical cancer vaccination efforts. The investment in cervical cancer vaccines aims to prevent the onset of cervical cancer, aiming to reduce the economic burden associated with treatment costs. Additionally, this strategic allocation of resources seeks to enhance overall public health outcomes and foster long-term cost-effectiveness by curbing the necessity for extensive medical interventions. For instance, as reported by the American Medical Association in March 2023, health spending in the United States witnessed a 2.7% increase in 2021, totaling $4.3 trillion, with an average of $12,914 per capita. Hence, the escalation in healthcare spending emerges as a driving force propelling the growth of the cervical cancer vaccine market.

Product innovation stands out as a significant and growing trend within the cervical cancer vaccine market, with prominent market players directing their efforts towards the development of pioneering products to reinforce their market positions. An example of this trend occurred in May 2022 when GlaxoSmithKline, a UK-based pharmaceutical company, obtained approval from China's National Medical Products Administration (NMPA) for a two-dose schedule of its vaccine, Cervarix. This vaccine, intended for girls aged nine to fourteen, has been authorized to prevent cervical cancer. This approval marks a significant milestone as Cervarix becomes the first imported HPV vaccine to utilize a two-dose regimen for this specific age group in mainland China.

Major companies engaged in cervical cancer vaccines are strategically focusing on collaboration and partnerships to deliver reliable services to their clientele. These strategic partnerships involve structured alliances between multiple commercial enterprises, typically established through various business agreements or contracts. For instance, in June 2023, Nykode Therapeutics ASA, a Norway-based provider specializing in next-generation vaccines, expanded its collaboration with Roche Holding AG, a Switzerland-based healthcare company, to advance VB10.16, an off-the-shelf therapeutic cancer vaccine. The collaborative effort aims to evaluate VB10.16 in combination with Roche's atezolizumab (Tecentriq), an anti-PD-L1 immunotherapy, in patients diagnosed with advanced cervical cancer. This partnership holds promise in developing a novel and effective treatment option for a type of cancer that has limited treatment alternatives and typically poor prognoses.

In November 2021, the United Nations Population Fund (UNFPA), a United Nations agency, and Roche Diagnostics entered into a partnership agreement with the aim of advancing efforts to eliminate cervical cancer in Eastern Europe and Central Asia. This partnership underscores their shared commitment to addressing the high burden of cervical cancer in the region and improving access to essential screening services. The goal is to ensure that women in Eastern Europe and Central Asia have increased access to HPV testing and early detection, leading to timely treatment and improved outcomes. Roche Diagnostics, based in Switzerland, is involved in the discovery, development, and manufacturing of in vitro tests for various diseases.

Major companies operating in the cervical cancer vaccine market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Novartis AG, Sanofi Pasteur, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Serum Institute of India (SII), Walvax Biotechnology Co Limited, Bavarian Nordic A/S, CureVac N.V, Profectus Biosciences Inc., Genexine Inc., Inovio Pharmaceuticals Inc., Aston Scientific Inc., Ultimovacs ASA, Nykode Therapeutics AS, Heat Biologics Inc., Northwest Biotherapeutics Inc., VBI Vaccines Inc., OncBioMune Pharmaceuticals Inc., Advaxis Inc., Immunovaccine Inc.

North America was the largest region in the cervical cancer vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cervical cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cervical cancer vaccine market consists of sales of a gardiquimod, V503, silgard, and Human papillomavirus vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cervical Cancer Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cervical cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cervical cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cervical cancer vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Cervarix; Gardasil; Gardasil 9
• 2) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End-Users: Hospital; Biotechnology Company; Academic And Research Organizations; Other End-Users
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; Novartis AG; Sanofi Pasteur
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cervical Cancer Vaccine Market Characteristics

3. Cervical Cancer Vaccine Market Trends And Strategies

4. Cervical Cancer Vaccine Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Cervical Cancer Vaccine Market Size and Growth

• 5.1. Global Cervical Cancer Vaccine Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cervical Cancer Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cervical Cancer Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cervical Cancer Vaccine Market Segmentation

• 6.1. Global Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cervarix
• Gardasil
• Gardasil 9
• 6.2. Global Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital
• Biotechnology Company
• Academic And Research Organizations
• Other End-Users

7. Cervical Cancer Vaccine Market Regional And Country Analysis

• 7.1. Global Cervical Cancer Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cervical Cancer Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cervical Cancer Vaccine Market

• 8.1. Asia-Pacific Cervical Cancer Vaccine Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cervical Cancer Vaccine Market

• 9.1. China Cervical Cancer Vaccine Market Overview
• 9.2. China Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cervical Cancer Vaccine Market

• 10.1. India Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cervical Cancer Vaccine Market

• 11.1. Japan Cervical Cancer Vaccine Market Overview
• 11.2. Japan Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cervical Cancer Vaccine Market

• 12.1. Australia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cervical Cancer Vaccine Market

• 13.1. Indonesia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cervical Cancer Vaccine Market

• 14.1. South Korea Cervical Cancer Vaccine Market Overview
• 14.2. South Korea Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cervical Cancer Vaccine Market

• 15.1. Western Europe Cervical Cancer Vaccine Market Overview
• 15.2. Western Europe Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cervical Cancer Vaccine Market

• 16.1. UK Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cervical Cancer Vaccine Market

• 17.1. Germany Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cervical Cancer Vaccine Market

• 18.1. France Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cervical Cancer Vaccine Market

• 19.1. Italy Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cervical Cancer Vaccine Market

• 20.1. Spain Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cervical Cancer Vaccine Market

• 21.1. Eastern Europe Cervical Cancer Vaccine Market Overview
• 21.2. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cervical Cancer Vaccine Market

• 22.1. Russia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cervical Cancer Vaccine Market

• 23.1. North America Cervical Cancer Vaccine Market Overview
• 23.2. North America Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cervical Cancer Vaccine Market

• 24.1. USA Cervical Cancer Vaccine Market Overview
• 24.2. USA Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cervical Cancer Vaccine Market

• 25.1. Canada Cervical Cancer Vaccine Market Overview
• 25.2. Canada Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cervical Cancer Vaccine Market

• 26.1. South America Cervical Cancer Vaccine Market Overview
• 26.2. South America Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cervical Cancer Vaccine Market

• 27.1. Brazil Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cervical Cancer Vaccine Market

• 28.1. Middle East Cervical Cancer Vaccine Market Overview
• 28.2. Middle East Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cervical Cancer Vaccine Market

• 29.1. Africa Cervical Cancer Vaccine Market Overview
• 29.2. Africa Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cervical Cancer Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Cervical Cancer Vaccine Market Competitive Landscape
• 30.2. Cervical Cancer Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi Pasteur
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Cervical Cancer Vaccine Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Moderna Inc.
• 31.6. BioNTech SE
• 31.7. CSL Limited
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Sinovac Biotech Ltd.
• 31.10. Bharat Biotech International Limited
• 31.11. Serum Institute of India (SII)
• 31.12. Walvax Biotechnology Co Limited
• 31.13. Bavarian Nordic A/S
• 31.14. CureVac N.V
• 31.15. Profectus Biosciences Inc.

32. Global Cervical Cancer Vaccine Market Competitive Benchmarking

33. Global Cervical Cancer Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cervical Cancer Vaccine Market

35. Cervical Cancer Vaccine Market Future Outlook and Potential Analysis

• 35.1 Cervical Cancer Vaccine Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Cervical Cancer Vaccine Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Cervical Cancer Vaccine Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer